1. Home
  2. TSLX vs NUVB Comparison

TSLX vs NUVB Comparison

Compare TSLX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

N/A

Current Price

$18.06

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

N/A

Current Price

$5.57

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
NUVB
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
TSLX
NUVB
Price
$18.06
$5.57
Analyst Decision
Buy
Buy
Analyst Count
11
10
Target Price
★ $19.77
$13.10
AVG Volume (30 Days)
363.2K
★ 4.0M
Earning Date
11-03-2026
11-02-2026
Dividend Yield
★ 9.82%
N/A
EPS Growth
N/A
★ 71.56
EPS
★ 0.15
N/A
Revenue
N/A
★ $62,902,000.00
Revenue This Year
N/A
$212.89
Revenue Next Year
$3.99
$41.68
P/E Ratio
$122.30
★ N/A
Revenue Growth
N/A
★ 698.96
52 Week Low
$16.04
$3.36
52 Week High
$23.19
$9.75

Technical Indicators

Market Signals
Indicator
TSLX
NUVB
Relative Strength Index (RSI) 46.69 36.84
Support Level $17.20 $5.28
Resistance Level $18.59 $5.77
Average True Range (ATR) 0.33 0.24
MACD -0.00 -0.04
Stochastic Oscillator 34.95 14.87

Price Performance

Historical Comparison
TSLX
NUVB

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: